TLIF yields 41666.67% · ABBV yields 3.06%● Live data
📍 TLIF pulled ahead of the other in Year 1
Combined, TLIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TLIF + ABBV for your $10,000?
TOCCA Life Holdings, Inc. operates sober living facilities in Lake Worth, Lantana, and Boynton Beach, Florida. The company provides clinical toxicology testing services to monitor the illicit drug use and transforms sobriety addicted clients and the community into productive members of society. It offers sober support services; operates an addiction treatment center; provides sober life coaching and transitional living programs; conducts sports events and fitness activities; and operates house recovery residence facilities and sober living recovery residences. It offers equipment, materials, and demonstrations in the areas of cooking, cleaning, household maintenance, business etiquette, basic math, basic banking, computer skills, writing skills, life coaching, transitional living management, graphic art, information technology, marketing, television production, interest rate theories, credit cost valuation, mortgage banking, career opportunities, business models, business infrastructures, business ethics, and entrepreneurship. It also offers prepaid services, which include hygiene, linen, grocery, and other products and services online. The company was formerly known as TOCCA Life Coaching, Inc. and changed its name to TOCCA Life Holdings, Inc. in January 2015. TOCCA Life Holdings, Inc. was founded in 2013 and is based in Lake Worth, Florida.
Full TLIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.